1 |
Luo W and Semenza GL (2012) Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 23, 560-566
DOI
ScienceOn
|
2 |
Warburg O (1956) On the origin of cancer cells. Science 123, 309-314
DOI
|
3 |
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW (2013) Cancer genome landscapes. Science 339, 1546-1558
DOI
ScienceOn
|
4 |
Teicher BA, Linehan WM and Helman LJ (2012) Targeting cancer metabolism. Clin Cancer Res 18, 5537-5545
DOI
ScienceOn
|
5 |
Dang L, Jin S and Su SM (2010) IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16, 387-397
DOI
ScienceOn
|
6 |
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812
DOI
ScienceOn
|
7 |
Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27, 4150-4154
DOI
ScienceOn
|
8 |
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360, 765-773
DOI
ScienceOn
|
9 |
Bleeker FE, Lamba S, Leenstra S et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30, 7-11
DOI
ScienceOn
|
10 |
Xu X, Zhao J, Xu Z et al (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 279, 33946-33957
DOI
ScienceOn
|
11 |
Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231
DOI
ScienceOn
|
12 |
Oermann EK, Wu J, Guan KL and Xiong Y (2012) Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 23, 370-380
DOI
ScienceOn
|
13 |
Watanabe T, Nobusawa S, Kleihues P and Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174, 1149-1153
DOI
ScienceOn
|
14 |
Losman JA and Kaelin WG Jr. (2013) What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27, 836-852
DOI
ScienceOn
|
15 |
Pollard PJ and Ratcliffe PJ (2009) Cancer. Puzzling patterns of predisposition. Science 324, 192-194
DOI
ScienceOn
|
16 |
Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324, 261-265
DOI
ScienceOn
|
17 |
Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744
DOI
ScienceOn
|
18 |
Cairns RA and Mak TW (2013) Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 3, 730-741
DOI
ScienceOn
|
19 |
Andronesi OC, Rapalino O, Gerstner E et al (2013) Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 123, 3659-3663
DOI
ScienceOn
|
20 |
Sasaki M, Knobbe CB, Itsumi M et al (2012) D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26, 2038-2049
DOI
ScienceOn
|
21 |
Sasaki M, Knobbe CB, Munger JC et al (2012) IDH1 (R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659
DOI
ScienceOn
|
22 |
Struys EA, Salomons GS, Achouri Y et al (2005) Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. Am J Hum Genet 76, 358-360
DOI
ScienceOn
|
23 |
Kitamura T, Tange T, Terasawa T et al (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140, 323-334
DOI
|
24 |
Losman JA, Looper RE, Koivunen P et al (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625
DOI
ScienceOn
|
25 |
Kranendijk M, Struys EA, Gibson KM et al (2010) Evidence for genetic heterogeneity in D-2-hydroxyglutaric aciduria. Hum Mutat 31, 279-283
DOI
ScienceOn
|
26 |
Kranendijk M, Struys EA, van Schaftingen E et al (2010) IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science 330, 336
DOI
ScienceOn
|
27 |
Rohle D, Popovici-Muller J, Palaskas N et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630
DOI
ScienceOn
|
28 |
Wang F, Travins J, DeLaBarre B et al (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622-626
DOI
ScienceOn
|
29 |
Davis MI, Gross S, Shen M et al (2014) Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289, 13717-13725
DOI
ScienceOn
|
30 |
Popovici-Muller J, Saunders JO, Salituro FG et al (2012) Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Med Chem Lett 3, 850-855
DOI
ScienceOn
|
31 |
Liu Z, Yao Y, Kogiso M et al (2014) Inhibition of cancerassociated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. J Med Chem 57, 8307-8318
DOI
ScienceOn
|
32 |
Deng G, Shen J, Yin M et al (2015) Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule. J Biol Chem 290, 762-774
DOI
ScienceOn
|